Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Sex May Influence Effectiveness of Common Heart Failure Drug
Clinical Breakthroughs

Sex May Influence Effectiveness of Common Heart Failure Drug

By Melissa RohmanApr 6, 2020
Share
Facebook Twitter Email
Sanjiv Shah, MD, the Neil J. Stone, MD, Professor in the Division of Cardiology, was a co-author of the study published in Circulation.

Women saw a greater benefit than men from a novel combination heart failure drug called sacubitril-valsartan, with a bigger reduction in risk of hospitalizations for heart failure and death from cardiovascular causes, according to a study published in Circulation.

The study, co-authored by Sanjiv Shah, ’00 MD, the Neil J. Stone, MD, Professor in the Division of Cardiology, may suggest that the effectiveness of pharmacologic treatments for heart failure with preserved ejection fraction (HFpEF) may depend on the patient’s sex.

Unlike heart failure with reduced ejection fraction, there is currently no approved treatment for HFpEF, in which the heart muscle contracts relatively normally but the ventricles do not relax normally during ventricular filling. The condition is also more prevalent in women than in men, according to Shah.

The reason for this disparity, according to Shah, is that women are actually less likely to develop the form of heart failure with reduced ejection fraction, making them more likely to develop HFpEF. Women with HFpEF also have lower levels of B-type natriuretic peptide levels, a beneficial protein the helps blood vessels relax and tells the kidney to get rid of fluid.

“Sacubitril-valsartan augments the action of B-type natriuretic peptide,” Shah said.

Additionally, women also have a higher “set-point” for their ejection fraction, or the contracting function of the heart. Therefore, women who develop HFpEF may actually have greater heart muscle problems than men in the same category.

For the current study, the investigators compared hospitalizations due to heart failure and death from cardiovascular causes in participants involved in the PARAGON-HF trial, which involved more than 4,700 men and women with HFpEF to take either sacubitril-valsartan or valsartan.

The investigators found that sacubitril-valsartan reduced the risk of heart failure hospitalization more among women compared to men. However, symptoms didn’t improve in women taking the drug.

“Even though there is plenty of scientific rationale for women benefiting more than men, the findings from the study suggest that the benefit in women may have been a chance finding,” Shah said, and noted that future studies may tease out more of the differences in treatment between men and women.

Currently, Shah and colleagues are studying the intersection of sex hormones, heart muscle structure and function during exercise, body composition and hormone signaling in men and women with HFpEF which, according to Shah, may aide in the development of new treatments.

This work was supported by an American Heart Association Go Red for Women Strategically Focused Research Network grant.

Cardiology Faculty Medicine Research
Share. Facebook Twitter Email

Related Posts

Dissolving Implantable Device Relieves Pain Without Drugs

Jun 30, 2022

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Comments are closed.

Latest News

Physician Assistant Students Embrace ‘Shades of Purple’

Jul 1, 2022

Dissolving Implantable Device Relieves Pain Without Drugs

Jun 30, 2022

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.